SUBSCRIBE
SUBSCRIBE
News   Drug Development

Roche, Biogen Idec, Inc. (Massachusetts) Report One Death In MS Drug Ocrelizumab Phase II Trial

October 18, 2010 | 
1 min read
BOSTON, Oct 15 (Reuters) - Roche Holding AG (ROG.VX) and Biogen Idec Inc (BIIB.O) reported data from a mid-stage trial of their experimental multiple sclerosis drug ocrelizumab on Friday that showed one patient died of an inflammatory condition.
Clinical research Phase II
Biogen Roche
MORE ON THIS TOPIC
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Yellow Forklift truck truckraises a box over a stack of boxes and red arrow down. Decrease in economic rates, low demand for goods, decrease in import or export. Reduced storage, logistics costs
Immunology and inflammation
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
July 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
 · 
8 min read
 · 
Tristan Manalac